The Joint (US:JYNT)2026-03-12 22:00Financial Data and Key Metrics Changes - Revenue from continuing operations increased by 3.1% in Q4 2025 compared to Q4 2024, reaching $15.2 million, while consolidated adjusted EBITDA rose by 7.8% to $3.6 million [9][20] - For the full year 2025, revenue was $54.9 million, up from $52.2 million in 2024, and consolidated net income improved to $2.9 million from a loss of $5.8 million in 2024 [21][22] - Unrestricted cash and cash equivalents at the end of Q4 2025 stood at $23.6 million, down from $25.1 million in the prior year [22] Business Line Data and Key Metrics Changes - System-wide sales decreased by 3.9% to $130 million in Q4 2025, while comp sales were down 3.8% [18] - For the full year, system-wide sales were flat at $532 million, with comp sales declining by 0.4% [18] Market Data and Key Metrics Changes - The total clinic count at year-end 2025 was 960, down from 967 clinics in the prior year, with 885 franchise clinics and 75 company-owned clinics [19] - The company refranchised 41 clinics and closed 36 clinics during 2025 [19] Company Strategy and Development Direction - The company is on track to complete the first phase of its transformation journey, Joint 2.0, by the end of 2026, transitioning to a pure-play franchisor model [5][28] - Future growth strategies include expanding operations into new channels and markets, focusing on health trends and integrated treatments [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in improving operating leverage and financial position through refranchising and cost-saving initiatives [28] - The company anticipates that 2026 will be more profitable than 2025 due to refranchising efforts and realignment of corporate costs [24] Other Important Information - The company repurchased 1.1 million shares for $9 million in Q4 2025 and a total of 1.3 million shares for $11.3 million in 2025 [9][22] - The company expects system-wide sales in 2026 to range from $519 million to $552 million, with comp sales projected between -3% to 3% [22] Q&A Session Summary Question: Can you share the attrition and new patient add metrics? - Management noted that new patient flow has been the weakest component of active member growth, but early signs from new marketing efforts are positive [33][34] Question: How are you evolving marketing initiatives for 2026? - The focus remains on shifting investment from local to national marketing to amplify brand awareness, with ongoing adjustments to creative messaging and addressing shifts in search behaviors due to AI [36][37] Question: How did the three-tiered pricing pilot go? - The $10 pricing increase showed more benefit compared to the $2 increase, and further testing is ongoing before broader rollout [39][40] Question: How did comp sales progress throughout the quarter? - Comp sales were down the most in November but improved in December, with expectations for better performance in the second half of the year [46][47] Question: What specific leading indicators give confidence that comps will improve in 2026? - Management highlighted early signs of improvement in leads and new patient acquisition, with expectations for better performance in the second half of the year due to easier comparisons [52][55] Question: Can you elaborate on growth initiatives and capital allocation? - Investments will focus on technology improvements and user interface enhancements for Wellness Coordinators, with ongoing negotiations for RD territory buybacks [70][73]